Please turn JavaScript on
header-image

tHEORetically Speaking -

follow.it gives you an easy way to subscribe to THEORetically Speaking -'s news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.

You can also unsubscribe anytime painlessly. You can even combine feeds from THEORetically Speaking - with other site's feeds!

Title: HealthEconomics.com - RWE, HEOR, and Market Access Content for Industry Professionals

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  4.78 / week

Message History

President Trump has introduced the “Great Healthcare Plan,” a one-page framework designed to lower costs following the 2026 expiration of ACA subsidies. The proposal shifts federal aid from insurers to consumers via direct HSA deposits, revives cost-sharing reduction payments, and codifies “most favored nation” drug pricing deals. It also mandates aggressive price tran...


Read full story

Oxford Biomedica, a leading contract manufacturer specializing in viral vectors for cell and gene therapies, has confirmed it is in preliminary discussions regarding a potential takeover by the private equity group EQT. While the company previously rejected multiple unsolicited bids for being too low, it is now evaluating whether EQT can provide a cash offer that refle...


Read full story

Bayer has entered a three-year strategic collaboration with Cradle to integrate its generative AI software into Bayer’s biologics R&D workflow. The partnership aims to enhance the discovery and optimization of therapeutic antibodies by utilizing “lab-in-the-loop” AI to design higher-quality molecules. By streamlining the design-test-learn cycle, the collaboration s...


Read full story

The U.S. Food and Drug Administration has released draft guidance aimed at increasing the use of Bayesian methodologies in clinical trials for drugs and biologics. Unlike traditional statistical frameworks, Bayesian analysis allows developers to combine current study data with prior information—such as previous clinical trials or real-world evidence—to draw conclusions...


Read full story

Novartis has entered a strategic global licensing agreement with SciNeuro Pharmaceuticals to develop a next-generation anti-amyloid antibody, SNP234, targeting Alzheimer’s disease. To secure the rights, Novartis is paying $165 million upfront, with the potential for $1.5 billion in additional milestone payments. The partnership centers on SciNeuro’s proprietary “shuttl...


Read full story